Prolonged survival after multimodal therapy for pleural mesothelioma: Don't give up the follow-up. A case report
- Resource Type
- Authors
- Sophie Laroumagne; Philippe Astoul; Hervé Dutau; Bertrand Chollet; Julien Guinde
- Source
- Annals of Medicine and Surgery
- Subject
- Mesothelioma
Extrapleural Pneumonectomy
medicine.medical_specialty
medicine.medical_treatment
Case Report
Context (language use)
03 medical and health sciences
0302 clinical medicine
Recurrence
Medicine
Radical surgery
Chemotherapy
business.industry
Multimodal therapy
General Medicine
medicine.disease
Radiation therapy
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
Surgery
Trimodal therapy
Long survival
Radiology
business
Rare disease
- Language
- ISSN
- 2049-0801
Malignant Pleural mesothelioma (MPM) is a rare disease which is associated with a poor prognosis. Front line chemotherapy represents the cornerstone in the management of MPM, and the place of radical surgery is controversial and reserve in early-stage disease. However prolonged survival (more than 24 months) can be observed in rare cases and only in the context of multimodal treatment including surgical management. We report the case of a patient suffering from an epithelial MPM with a 14-years progression-free survival after trimodal treatment including extrapleural pneumonectomy followed by chemotherapy and radiotherapy. This case illustrates that despite being an aggressive disease, multimodal management including radical surgery may allow a prolonged response in MPM but requires a whole-life surveillance.
Highlights • Malignant pleural mesothelioma (MPM) is a rare disease. • Prognosis of MPM is very poor despite new therapeutic agents. • The place of radical surgery still remains controversial. • Prolonged survival can be obtained by multimodal therapy including radical surgery. • Complete remission after treatment requires a whole-life surveillance.